

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/196937 A1

(43) International Publication Date
12 October 2023 (12.10.2023)

(51) International Patent Classification:

G01N 33/68 (2006.01) C12Q 1/6876 (2018.01)

(21) International Application Number:

PCT/US2023/065483

(22) International Filing Date:

06 April 2023 (06.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/328,238	06 April 2022 (06.04.2022)	US
63/393,968	31 July 2022 (31.07.2022)	US

(71) Applicant: **LARIMAR THERAPEUTICS, INC.**
[US/US]; Three Bala Plaza East, Suite 506, Bala Cynwyd,
PA 19004 (US).

(72) Inventors: **BETTOUN, Joan David**; 8106 Cadwalader
Avenue, Elkins Park, PA 19027 (US). **BAILE, Matthew
Garrett**; 841 Delmont Drive, Wynnewood, PA 19096 (US).
CHEN, Ruihua; 16 Labrador Drive, Kendall Park, NJ
08824 (US).

(74) Agent: **MELLO, Jill Ann** et al.; McCarter & English, LLP,
265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: FRATAXIN-SENSITIVE MARKERS FOR MONITORING FRATAXIN REPLACEMENT THERAPY

(57) Abstract: The present disclosure is based, at least in part, on providing a set of markers, also referred to herein as FXN-sensitive genomic markers (or FSGMs), the respective expression levels of which are positively or negatively correlated to frataxin (FXN) levels in a cell. Therefore, these FSGMs can be used to determine, evaluate, and/or monitor the effectiveness of FXN replacement therapy in a subject.

WO 2023/196937 A1